[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593926":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":48,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Zhongda Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","ACTIVE_COMPARATOR",null,[13],"Drug: Bismuth quadruple therapy",{"label":15,"type":16,"description":11,"interventionNames":17},"Experimental group","EXPERIMENTAL",[18],"Drug: Saccharomyces boulardii",[20,24],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Bismuth quadruple therapy",[9],{"type":21,"name":25,"description":25,"armGroupLabels":26,"otherNames":11},"Saccharomyces boulardii",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Lu Chen","CONTACT","13611569073","13611569073@163.com",[34],{"facility":35,"status":11,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Zhongda Hospital Southeast University","Nanjing","Jiangsu","210000","China",{"type":41,"coordinates":42},"Point",[43,44],118.77778,32.06167,{"lat":44,"lon":43},[47],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Chen Lu","Director","100593926",false,"NCT07012785","Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection","Inclusion Criteria:\n\n1. Aged 18-70 years, regardless of gender;\n2. Positive 13C\u002F14C urea breath test result;\n3. No previous history of H. pylori eradication treatment;\n4. Agreement to participate in this study and signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of ≥ 1 instance of failed H. pylori eradication;\n2. Use of antibiotics (including antibacterial traditional Chinese medicines), nonsteroidal anti-inflammatory drugs (NSAIDS), bismuth agents, H2 receptor antagonists (H2RAs), proton-pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CAB) within 4 weeks before treatment;\n3. Plans to conceive, pregnancy, or breastfeeding;\n4. Severe liver, kidney, or cardiovascular diseases; malignancies; and alcoholism;\n5. Allergies to the drugs used in this study or a history of penicillin allergy;\n6. The inability to correctly express one's symptoms and wishes, such as inability due to mental illness or severe neurosis.","ALL","18 Years","70 Years",{"count":61,"type":62},208,"ESTIMATED","INTERVENTIONAL",[65],"NA","To assess the efficacy and safety of Saccharomyces boulardii combined with triple therapy containing minocycline in the initial eradication of Helicobacter pylori (H. pylori) infection",[68],"H. Pylori Infection","NOT_YET_RECRUITING","2025-06-02",{"date":72,"type":73},"2025-06-10","ACTUAL",{"date":75,"type":62},"2025-06",{"date":77,"type":62},"2025-12",{"name":5,"class":6},1]